Uveitis in Children and Adolescents

Rheum Dis Clin North Am. 2021 Nov;47(4):619-641. doi: 10.1016/j.rdc.2021.07.005. Epub 2021 Aug 27.

Abstract

Childhood noninfectious uveitis leads to sight-threatening complications. Idiopathic chronic anterior uveitis and juvenile idiopathic arthritis-associated uveitis are most common. Inflammation arises from an immune response against antigens within the eye. Ophthalmic work-up evaluates anatomic involvement, disease activity, ocular complications, and disease course. Local and/or systemic glucocorticoids are initial treatment, but not as long-term sole therapy to avoid glucocorticoids-induced toxicity or persistent ocular inflammation. Children with recurrent, refractory, or severe disease require systemic immunosuppression with methotrexate and/or anti-tumor necrosis factor monoclonal antibody medications (adalimumab, infliximab). Goals of early detection and treatment are to optimize vision in childhood uveitis.

Keywords: Autoimmune; Ophthalmology; Pediatrics; Rheumatology; Uveitis.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adalimumab
  • Adolescent
  • Arthritis, Juvenile* / complications
  • Arthritis, Juvenile* / diagnosis
  • Arthritis, Juvenile* / drug therapy
  • Child
  • Humans
  • Infliximab
  • Methotrexate
  • Uveitis* / diagnosis
  • Uveitis* / drug therapy
  • Uveitis* / epidemiology

Substances

  • Infliximab
  • Adalimumab
  • Methotrexate